Expression-based signatures and genomic predictors are increasingly incorporated into clinical practice to predict benefit from chemotherapy. We evaluated 125 published gene expression signatures in a patient-level meta-analysis of gene expression data from breast cancer biopsies prior to neoadjuvant chemotherapy (NAC) to understand the contribution of proliferation and other processes in patient response to NAC. The majority of signatures associated with pathologic complete response (pCR) are proliferation-associated within each receptor-based or PAM50 breast cancer subgroup. However, proliferation-independent signatures offer important insights into additional biological processes that contribute to chemosensitivity and resistance.
Introduction
In spite of remarkable progress in targeted therapeutics in breast cancer, including hormonal and HER2-directed therapies, chemotherapy continues to play a critical role in the management of over one third of all women with breast cancer.(1-3) Neoadjuvant chemotherapy (NAC) is associated with improved rates of conversion from mastectomy to breast conservation and also offers prognostic information: in a large meta-analysis, patients who achieved pCR following NAC had improved disease-free and overall survival relative to those with residual disease.(4) In addition, NAC provides a window through which to evaluate the intrinsic chemosensitivity of breast cancer, as patients receive no treatments prior to NAC and there is a discrete endpointpathologic complete response (pCR) or residual disease (RD).
Gene expression signatures are sets of genes whose expression patterns associate with a specific biological process or phenotype. Over 15 years ago, Perou and colleagues used gene expression profiling to describe molecular subtypes within breast cancer that initially correlated with overall survival and ultimately were shown to reflect sensitivity to NAC. multiple individual gene expression signatures could provide insight into the complex network of pathways and processes involved in chemosensitivity and resistance. (14) (15) (16) In this patient-level meta-analysis, we assembled publicly available mRNA microarray gene expression data from over 1400 breast cancer biopsies obtained prior to NAC, the largest dataset of its type to date. We collected study-reported response to NAC defined as pCR versus RD as well as patient clinicopathologic characteristics. With this large clinically annotated dataset, we interrogatated pathways involved in response to chemotherapy by evaluating and comparing 125 published breast cancer-related gene expression signatures implicated in chemosensitivity and resistance. We demonstrate that proliferation accounts for the vast majority of the predictive power of gene signatures within each subset of breast cancer and identify proliferationindependent signatures predictive of response to NAC, including immune signatures in ER+/HER2-breast cancers and signaling pathway signatures in triple-negative breast cancers.
Methods

Microarray Data
Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
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(U133 and U133Plus2.0 arrays) and Agilent platforms were included to limit cross-platform variability. Individual samples were excluded if biopsy was obtained after NAC, if the patient received HER2-directed therapy (e.g. trastuzumab), or if pathologic response data were not available. Duplicate records were removed by careful review of GEO annotation and any records with Pearson correlation coefficient of one. In total, 1417 records from 17 studies were included for analysis (Table 1., Supplementary Table 1 ., NCBI GEO accession numbers GSE8465, GSE16446, GSE18728, GSE19697, GSE20194, GSE20271, GSE21974, GSE21997, GSE22093, GSE22226, GSE22358, GSE22513, GSE23988, GSE25066, GSE28796, GSE32646). Raw Affymetrix microarray data were processed with RMA normalization and Agilent microarray data was subjected to Lowess-normalization and log 2 transformation. Samples were batchmedian centered by study to allow cross-study comparison. (19, 20) To determine intrinsic breast cancer subtype, the 'Bioclassifier' package from Parker and colleagues (21) was used with no additional calibration parameters given that each dataset was relatively balanced with respect to ER-status by pathology: 49% and 58% ER-positive for Affymetrix and Agilent datasets, respectively ( 'positive' or 'negative' based on study-specific definitions. For ER or PR immunohistochemistry (IHC), 0 was defined as 'negative' and 2-3 defined as 'positive', while IHC of 1 was considered indeterminate. A FISH HER2/CEP17 ratio of greater than 2.0 was defined as positive. Chemotherapy was patient-specified in 15 studies and based on the associated publication in two studies.
Gene Expression Signatures
Gene expression signatures were compiled from published studies describing a variety of processes implicated in chemosensitivity or resistance (11, 15) and from curated databases, including MSigDB (27) and GeneSigDB. (28) We included only signatures that were defined from mammary or breast cancer cell lines, breast cancer samples, or had been previously validated in breast cancer expression datasets. Signatures were categorized based on the proposed phenotype characterized by that signature (Figure 2A. ). To establish a single value for each signature, we calculated the mean of the gene expression values identified as 'up' in each signature based on the original publication. As a sensitivity analysis, we evaluated those signatures that had both 'up' and 'down' genes (32/125 signatures; 25.6%) and calculated the mean of the 'down' genes subtracted from the mean of the 'up' genes. Bidirectional signature scores were highly correlated with scores calculated using only 'up' genes (median Pearson's r of 0.7412). Based on these data, we pursued subsequent analyses using only 'up' genes. We also included 'random' signatures of varying sizes (5, 10, 50, 100, 500 genes) composed of genes Table S2 .) as well as code for analyses in R (Supplemental Data).
Normal Mammary Epithelium Acinar Morphogenesis Assay
MCF-10A mammary epithelial cells were cultured in MatriGel 
Identification of Proliferation-Independent Signatures
To determine proliferation-associated versus proliferation-independent signatures, we performed a proliferation adjustment using the method proposed by Venet, et al.(31) Briefly, a linear model was constructed using the proliferation signature value for each sample fitted to the expression of each gene using the 'lm' function in R (version 3.1.3). Each expression measurement was then substituted by the sum of its residual and mean expression across the dataset. This approach was performed using two independent proliferation signatures, the 11-gene PAM50 proliferation index (32) 
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To determine if we could improve predictive performance by combining signatures, we developed a proliferation-immune 'meta-signature' consisting of 18 genes -11 from the PAM50 proliferation signature (BIRC5, CCNB1, CDC20, NUF2, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS, and UBEC2) and 7 from the GeparSixto immune activation signature (CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21). (32, 34) To evaluate the performance of this 'meta-signature', we combined ER+/HER2-cases from both Affymetrix and Agilent datasets (total n=642) and we randomly partitioned the combined ER+/HER2-dataset into equal training/validation subsets (n=321) then calculated the association of the 'Proliferation-Immune' meta-signature and the other 125 signatures via t-test. We repeated this approach for 1000 iterations then calculated an average FDR p-value for each signature as a measure of consistent performance.
Statistical Analysis
All microarray data processing and statistical analyses were performed in R version 3.1.3.
Contrasts in patient and tumor characteristics were evaluated using Pearson chi-squared tests.
Correlation among gene expression signatures was calculated using Pearson's coefficient, and hierarchical clustering was performed using average linkage. The association of signatures to continuous and categorical factors was evaluated using Student's t-test and analysis of variance, respectively. The association of individual genes significantly associated with NAC response were identified using 'limma' package and by t-test. (35) All calculations of association with response were multiple-testing corrected using Benjamini-Hochberg procedure for false discovery rate.
Research. 
Results
Patient and Tumor Characteristics
This meta-analysis includes microarray expression data from breast cancer biopsies obtained prior to NAC from 1419 breast cancer samples in 17 studies (Figure 1 ., Table 1 ., and Supplementary Table S1.). The data were divided into two independent datasets based on microarray platform for validation purposes: an 'Affymetrix Dataset' (12 studies with 1033 total samples) and an 'Agilent Dataset' (5 studies with 386 total samples). The two datasets were relatively balanced with respect to age, grade, pathologic ER and HER2 receptor status, and clinical subtype ( Table 2. ). HER2+ breast cancers were relatively under-represented relative to general incidence as we excluded those patients who received HER2-directed therapy, while TNBCs were relatively over-represented given that patients with TNBC are more likely to receive neoadjuvant chemotherapy. The chemotherapeutic agents that these patients received are similar to those agents that are currently administered in most centers. Clinicopathologic characteristics known to be associated with response to NAC -including tumor grade, receptor status, receptor-based subtype, and PAM50 status -were all significantly associated with response to NAC in both the Affymetrix and Agilent datasets (all p<0.05; Supplementary Table 
S3.).
A Large Proportion of Gene Expression Signatures Correlate Highly with Proliferation
Response to Neoadjuvant Chemotherapy is Strongly Associated With Proliferation
We evaluated the five proliferation signatures described above in 1419 breast tumors. More highly proliferative tumors were associated with a greater proportion of pCR to NAC in both the Affymetrix and Agilent datasets ( Figure 3C . and 3D.; ANOVA p=1.6x10 -13 and p=3.2x10 Table S4A .). As a sensitivity analysis, we also compared proliferation above/below median; higher proliferation remained significantly associated with a greater proportion of pCR for both receptor-based subgroups (p = 0.0004) and PAM50 subgroups In analysis across subtypes, the 11-gene PAM50 signature outperformed MKI67 and AURKA and was comparable to PCNA (p=4.3x10 -5 vs. 1.3x10 -5 , respectively), suggesting that expression- 
Proliferation-Associated Versus Proliferation-Independent Signatures Delineate Neoadjuvant Chemotherapy Response
We evaluated proliferation-associated versus proliferation-independent signatures by two distinct Based on evidence that immune signatures are a proliferation-independent predictor of pCR in ER+/HER2-disease, we developed a proliferation-immune 'meta-signature' as a proof-ofconcept application of these data. This proliferation-immune 'meta-signature' consists of 18 genes -11 that comprise the PAM50 proliferation signature and 7 that comprise the GeparSixto immune activation signature. (10, 32) We combined ER+/HER2-cases from both Affymetrix and Agilent datasets (total n=642) and iteratively evaluated the performance of the proliferationimmune 'meta-signature' in randomly assigned, equally sized (n=321) training/validation subsets. Over 1000 iterations, the proliferation-immune 'meta-signature' signature demonstrated a stronger association with pCR than any other individual signature in ER+/HER2-breast cancers (Supplementary Figure S3G. ).
Discussion
We compiled gene expression data from 1419 breast cancer biopsies obtained prior to NAC excluding patients who received HER2-directed therapy, the largest data set of its kind, and calculated 125 gene expression signatures for each sample. We demonstrate that proliferation signatures are highly associated with pCR in all subgroups of breast cancer. These proliferation signatures reflect a broad range of proliferation in an in vitro model of mammary epithelial cell proliferation. We further demonstrate that proliferation differences account for the majority of variation in chemosensitivity in ER+/HER2-breast cancer and remains important -but less soin TNBCs. Importantly, we provide an approach to distinguish proliferation-related from proliferation-independent gene expression signatures and identify immune-related signatures as an important proliferation-independent predictor of sensitivity to neoadjuvant chemotherapy in 
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In this study, using a linear modeling approach to identify proliferation-associated signatures and genes we find that the majority of the predictive capacity for response to neoadjuvant chemosensitivity within ER+ breast cancer is associated with proliferation: 90% of signatures and >95% of individual genes significantly associated with response to NAC can be attributed to proliferation. The striking degree to which proliferation accounts for predictive capacity of gene expression is supported by stratifying into the ER+ PAM50 subtypes, luminal A and B, which 
comprised of activating cytokines, chemokines, and immune response genes (Supplementary Table S1 .). In transcriptional analyses of tumor biopsies, it is difficult to discern whether these signatures reflect tumor cell-intrinsic expression differences or, alternately, transcriptional programs of infiltrating lymphocytes. Tumor infiltrating lymphocytes (TILs), evidence of immune activation, have been shown to be a predictive marker of response to NAC primarily in HER2+ and TNBC breast cancer but to date the association has been less robust in ER+/HER2-breast cancers. (49, 50) We are currently evaluating the underlying cause or driver of these immune signatures. 
Conclusions
In this gene expression-based meta-analysis, proliferation differences account for the majority of predictive capacity of gene expression signatures in neoadjuvant chemosensitivity for 
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ER+/HER2-breast cancers and, to a lesser extent TNBCs. In ER+/HER2-breast cancer, proliferation-independent signatures predictive of response were all related to immune activation. In TNBC, sensitivity and resistance to neoadjuvant chemotherapy is complex and associated with a diverse set of proliferation-associated and proliferation-independent signatures.
